Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
114 hedge funds and large institutions have $423M invested in Concert Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 11 closing their positions.
327% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 11
93% more capital invested
Capital invested by funds: $219M → $423M (+$204M)
61% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 23
59% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $769K
44% more funds holding
Funds holding: 79 → 114 (+35)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$14.3M |
| 2 |
BlackRock
New York
|
+$13.1M |
| 3 |
Millennium Management
New York
|
+$10.1M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$8.05M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$26.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$23.5M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.43M |
| 4 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$5.21M |
| 5 |
SM
Senvest Management
New York
|
-$4.82M |
CNCE Hedge Fund Activity: Q4 2017 in Review
114 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2017, worth a combined $423M — up 93% from $219M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CNCE positions and 11 closed out — a net gain of 36 holders — while 37 added to existing stakes and 23 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $26.9M.
- 114 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2017, up from 79 in Q3 2017.
- Funds reported $423M of Concert Pharmaceuticals, Inc. stock for Q4 2017, up 93% quarter-over-quarter.
- 47 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2017 and 11 closed out, a net change of +36 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2017 was Laurion Capital Management, an estimated $14.3M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2017 was Great Point Partners, an estimated $26.9M sold.
Based on aggregated 13F filings for Q4 2017.